Back to results
US 2020/0046832 A1Published application
Compositions comprising anti-cd38 antibodies and lenalidomide
AssigneesSanofi, The Regents of the University of California
InventorsByron C. HANN, Blake TOMKINSON, Thomas G. MARTIN, III, Blake T. AFTAB
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
Claims24
1:
- A method of treating a cancer in a subject which comprises administering one or more anti-CD38 antibodies and one or more lenalidomide compounds to the subject, wherein malignant cells of the cancer express CD38.
2-3. (canceled)
4:
- The method of claim 1, wherein the cancer is a relapsed multiple myeloma or a refractory multiple myeloma.
5:
- The method of claim 1, wherein the one or more lenalidomide compounds is lenalidomide.
6:
- The method of claim 1, wherein the one or more anti-CD38 antibodies are administered in an effective amount, preferably a synergistic amount.
7:
- The method of claim 1, wherein the one or more anti-CD38 antibodies and/or the one or more lenalidomide compounds are administered in a therapeutically effective amount.
8:
- The method of claim 1, wherein at least one of the one or more anti-CD38 antibodies is capable of killing a CD38+ cell by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).
(canceled)
10:
- The method of claim 1, wherein at least one of the one or more anti-CD38 antibodies is selected from the group consisting of:
- a) an antibody comprising a heavy chain comprising three sequential CDRs having amino acid sequences consisting of SEQ ID NOs:
- 13, 15 and either SEQ ID NO:
- 14 or SEQ ID NO:
- 81, and a light chain comprising three sequential CDRs having amino acid sequences consisting of SEQ ID NOs:
- 16, 17 and 18;
- b) an antibody comprising a heavy chain comprising three sequential CDRs having amino acid sequences consisting of SEQ ID NOs:
- 25, 26 and 27, and a light chain comprising three sequential CDRs having amino acid sequences consisting of SEQ ID NOs:
- 28, 29 and 30;
- c) an antibody comprising a heavy chain comprising three sequential CDRs having amino acid sequences consisting of SEQ ID NOs:
- 1, 2 and 3, and a light chain comprising three sequential CDRs having amino acid sequences consisting of SEQ ID NOs:
- 4, 5 and 6;
- d) an antibody comprising a heavy chain comprising three sequential CDRs having amino acid sequences consisting of SEQ ID NOs:
- 7, 8 and 9, and a light chain comprising three sequential CDRs having amino acid sequences consisting of SEQ ID NOs:
- 10, 11 and 12;
- e) an antibody comprising a heavy chain comprising three sequential CDRs having amino acid sequences consisting of SEQ ID NOs:
- 19, 20 and 21, and a light chain comprising three sequential CDRs having amino acid sequences consisting of SEQ ID NOs:
- 22, 23 and 24;
- and
- f) an antibody comprising a heavy chain comprising three sequential CDRs having amino acid sequences consisting of SEQ ID NOs:
- 31, 32 and 33, and a light chain comprising three sequential CDRs having amino acid sequences consisting of SEQ ID NOs:
- 34, 35 and 36.
19 more elements
11:
- The method of claim 10, wherein said antibody comprises a heavy chain having a VH variable region represented by SEQ ID NO:
- 66, and a light chain having a VL variable region represented by either SEQ ID NO:
- 62 or SEQ ID NO:
- 64.
1 more element
12:
- The method of claim 10, wherein said antibody comprises a heavy chain having a VH variable region represented by SEQ ID NO:
- 72, and a light chain having a VL variable region represented by either SEQ ID NO:
- 68 or SEQ ID NO:
- 70.
1 more element
13:
- The method of claim 1, wherein the one or more anti-CD38 antibodies are administered intravenously.
14:
- The method of claim 1, wherein the one or more lenalidomide compounds are administered orally.
15:
- The method of claim 1, wherein the one or more anti-CD38 antibodies and the one or more lenalidomide compounds are administered sequentially.
16:
- The method of claim 1, and further comprising administering a dexamethasone compound, preferably dexamethasone, to the subject.
17:
- The method of claim 16, wherein the dexamethasone compound is administered orally.
18:
- The method of claim 16, wherein the dexamethasone compound is administered at a low dose.
19:
- The method of claim 16, wherein the one or more anti-CD38 antibodies, the one or more lenalidomide compounds, and the dexamethasone compound are administered sequentially.
20:
- The method of claim 1, and further comprising administering an anti-coagulation agent to the subject.
21:
- The method of claim 20, wherein the anti-coagulation agent is selected from the group consisting of aspirin, warfarin, and low molecular weight heparin.
22:
- The method of claim 20, wherein the one or more anti-CD38 antibodies, the one or more lenalidomide compounds, and the anti-coagulation agent are administered sequentially.
23:
- A composition comprising
- a) at least one anti-CD38 antibody, preferably the antibody is capable of killing a CD38+ cell by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC);
- and
- b) at least one lenalidomide compound, preferably lenalidomide;
- and, optionally
- c) a dexamethasone compound, preferably dexamethasone;
- and, optionally
- d) an anti-coagulation agent.
5 more elements
24:
- A kit comprising
- a) a first composition comprising at least one anti-CD38 antibody, preferably the antibody is capable of killing a CD38+ cell by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC);
- and
- b) a second composition comprising at least one lenalidomide compound, preferably lenalidomide.
1 more element
25-28. (canceled)
Dependencies are inferred from the claim text.